An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches

Review expert insights on the latest developments in managing myelodysplastic syndromes with a focused commentary downloadable slides podcast and on-demand webcast from a live CCO symposium at ASH 2022.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

This activity is supported by independent educational grants from

Bristol Myers Squibb

Geron

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Learning Objectives

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with NSCLC and thyroid cancer
  • Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC and thyroid cancer and RET inhibition in RET-altered lung and thyroid cancer
  • Formulate strategies for integrating TRK and RET inhibitors into practice that include patient discussions, adverse event monitoring and management, and methods to enroll qualified patients on clinical trials
  • Develop treatment strategies for patients with cancer who develop acquired resistance to first-generation TRK and RET inhibitor therapy

  • Manage treatment-related symptoms associated with the treatment of RET-altered or
    NTRK fusion–positive cancer

  • Refer eligible patients with NTRK fusion–positive and RET-altered NSCLC and thyroid cancer for ongoing clinical trials